- China
- /
- Medical Equipment
- /
- SZSE:300412
Zhejiang Canaan Technology Second Quarter 2024 Earnings: EPS: CN¥0.03 (vs CN¥0.012 in 2Q 2023)
Zhejiang Canaan Technology (SZSE:300412) Second Quarter 2024 Results
Key Financial Results
- Revenue: CN¥333.9m (up 20% from 2Q 2023).
- Net income: CN¥17.9m (up 114% from 2Q 2023).
- Profit margin: 5.4% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue.
- EPS: CN¥0.03 (up from CN¥0.012 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Zhejiang Canaan Technology shares are up 15% from a week ago.
Risk Analysis
Be aware that Zhejiang Canaan Technology is showing 2 warning signs in our investment analysis and 1 of those is a bit unpleasant...
Valuation is complex, but we're here to simplify it.
Discover if Zhejiang Canaan Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300412
Zhejiang Canaan Technology
Engages in the research and development, production, and sale of pharmaceutical equipment in China and internationally.
Mediocre balance sheet and slightly overvalued.